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To evaluate the applicability ofdisability adjusted life-years (DALYs) as a measure to compare
positive and negative health effects of drinking water disinfection, we conducted a case study
involving ahypothetical drinking water supplyfrom surface water. This drinkingwatersupply is
typical in The Netherlands. We compared the reduction of the risk of infection with
Cryptosporidiumparvum by ozonation ofwater to the concomitant increase in risk ofrenal cell
cancer arising from the production ofbromate. We applied clinical, epidemiologic, andtoxicolog-
ic data on morbidity and mortality to calculate the net health benefit in DALYs. We estimated
the median risk ofinfection with C parvum as 10-3/person-year. Ozonation reduces the median
risk in the baseline approximately 7-fold, but bromate is produced in a concentration above cur-
rent guideline levels. However, the health benefits of preventing gastroenteritis in the general
population and premature death in patients with acquired immunodeficiency syndrome outweigh
health losses by premature death from renal cell cancer by a factor of > 10. The net benefit is
approximately 1 DALY/million person-years. The application ofDALYs in principle allows us to
more explicitly compare the public health risks and benefits ofdifferent management options. In
practice, the application ofDALYs may be hampered by the substantial degree ofuncertainty, as
is typical for risk assessment. Key work: bromate, Cryptosporidiumparvum, disinfection, drink-
mg water, ozone, quality oflife, risk assessment. Environ Health Perspect 108:315-321 (2000).
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The microbiologic safety ofdrinking water is
of paramount importance to public health
(1). Source protection is generally accepted
as the primary strategy to obtain microbio-
logically safe drinking water. However,
many sources (surface waters in particular)
are highly polluted and need extensive treat-
ment before distribution to the consumer.
Chemical disinfection is prominent in these
treatment schemes. Highly oxidizing chemi-
cals such as chlorine and ozone kill a variety
of pathogenic microorganisms during
treatment, and chlorine is applied in many
countries as an additional safeguard in the
distribution system. An important drawback
of the use of these chemicals is the genera-
tion ofdisinfection by-products, which have
suspected adverse effects on human health.
This situation calls for a formal quantitative
framework to compare the positive and nega-
tive health effects ofdrinking water disinfec-
tion and to assist in the design and operation
oftreatment plants (2).
Microbiologic risks are expressed as the
annual individual probability ofinfection for
a given consumption of drinking water.
Chemical risks related to genotoxic carcino-
gens are usually associated with an increase
in cancer incidence attributable to a lifetime
exposure. The public health impact of these
disease end points is very different and can-
not be compared directly. Hence, decision
making is difficult. We evaluated the applic-
ability of a single measure of attributable
disease burden to compare and balance
health risks and benefits on a public health
basis. The disability adjusted life-year
(DALY) consists of the loss of healthy life
years due to either premature mortality or
morbidity. The DALY integrates several
dimensions ofthe public health impact, such
as the number of affected persons and the
severity and duration of adverse health
effects, and uses time as a unit of measure-
ment. We illustrate our approach by a case
study of ozonation of a hypothetical drink-
ing water supply using surface water. We
used Monte Carlo simulation to assess the
uncertainty in our risk estimates, to account
for biologic and seasonal variation in expo-
sure and effects, and to accommodate uncer-
tainty in parameter values. In accordance
with the framework proposed by the U.S.
National Research Council (3), we discuss
the four consecutive elements of the risk
assessment process.
Hazard Identification
We considered a hypothetical drinking
water supply that is typical for drinking
water in The Netherlands. In this supply,
raw water is abstracted from an internation-
al river that has been polluted by domestic
and industrial sources and by agricultural
run-off. The water is treated by storage in
three consecutive reservoirs, coagulation,
sedimentation, rapid sand filtration, ozona-
tion (only when disinfected), granular
activated carbon filtration, and ultraviolet
(UV) postdisinfection. The water is then
distributed to the consumer without any
residual disinfectant in the distribution sys-
tem. Drinking water may harbor many
pathogenic microorganisms. In this paper,
we considered only one pathogen and one
of the many potential disinfection by-prod-
ucts that are associated with ozonation. We
illustrated the methodology but did not
make a comprehensive assessment of a par-
ticular situation. We selected a microbial
and chemical agent of major public health
significance in surface water supplies. Other
agents occur in lower concentrations and/or
induce smaller health effects. Hence, this
restriction does not largely affect the validity
ofthe final conclusions.
Cryptosporidium parvum is a protozoan
parasite that produces environmentally resis-
tant and highly infectious oocysts. Other
pathogenic microorganisms, such as viruses
and Campylobacterjejuni, may also be pre-
sent in similar concentrations in water from
storage reservoirs. However, these organisms
are inactivated by postdisinfection processes
such as UV irradiation in our scenario and
hence cause smaller public health problems.
Adequate control of C parvum is therefore
of critical importance in most surface-water
supplies. Infection with C. parvum may
result in self-limiting gastroenteritis in
immunocompetent persons. In those who
are immunocompromised, the infection is
not easily cleared and usually results in
severe life-threatening gastroenteritis. In the
immunocompromised group, we only
considered acquired immunodeficiency syn-
drome (AIDS) patients because a severe clin-
ical course of cryptosporidiosis is associated
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with CD4 counts < 53 cells/mL (4), which
is typical only in the advanced stages of
AIDS.
C parvum has caused major outbreaks of
waterborne disease in Europe and in North
America (5,6). Cparvum oocysts are resistant
to chlorination but may be inactivated by
ozonation, which is increasingly used as an
alternative disinfectant. However, ozone
reacts with bromide ions to produce bromate
(7). Bromate induces tumors in the rat kid-
ney, thyroid, and mesothelium (8,9) and is a
renal carcinogen in the mouse (9). In accor-
dance with the World Health Organization
(WHO) (1), we concentrated on renal cell
cancer as an outcome ofchronic exposure to
bromate. Bromate is considered the most
important by-product of ozonation (10).
Other by-products from ozonation may
include aldehydes, bromoform, and bromi-
nated acetic acids, none ofwhich are classified
as genotoxic carcinogens. Pilot plant experi-
ments (11) have demonstrated that at usual
ozone dosesonlyformaldehyde is produced in
measurable quantities, although at levels far
belowtheWHO guidelineof900pg/L (1).
Exposure Assessment
The model used for assessment of exposure
to C. parvum and bromate is described in
Table 1. Table 1 also shows Equations 1-9.
Not all parameter values are available for one
single drinking water production plant;
therefore, we used data from several plants to
represent a hypothetical but typical situation
in The Netherlands. When necessary, we
used additional data from the international
literature. Table 2 presents a point estimate
for each parameter as well as the probability
distributions used in the uncertaintyanalysis.
C. parvum. We estimated the concentra-
tion of C. parvum oocysts in drinking water
from their concentration in raw water and
their reduction by treatment. The concentra-
tion of C. parvum oocysts, measured at the
outlet of a series ofstorage reservoirs with a
mean retention time of 5 months and cor-
rected for recovery of the detection method
and for viability (12) can be described by a
lognormal distribution. The removal of C
parvum oocysts by coagulation-sedimenta-
tion-rapid sand filtration is estimated by the
removal of spores of sulfite-reducing
clostridia under full scale conditions (13).
We used Equation 1 to estimate the median
concentration of Cparvumoocysts in drink-
ingwaterwithout ozonation as 1.1 x 10-3/L.
We used a two-step approach to estimate
the effective ozone concentration in water
(14). Ozone was added at a constant dose of
3.1 mg/L to the first ofaseries offourcontact
chambers, then partially consumed by initial
rapid oxidation reactions (ozone demand).
Parameter values in the ozone demand model
and the subsequent exponential decay model
were based on linear regression analysis of
pilot-plant data (14), assuming a pH of 7.5
and a temperature of 10-12°C. The SD of
the residuals in the regression equation quan-
tified the uncertainty in the predicted values
(15). We modeled the variability in the resi-
dence time distribution in the ozone contact
chambers bythe inverse Gaussian distribution
(16). The Hom formula (Equation SB)
modeled inactivation ofC. parvumoocysts by
ozone, using the geometric mean as an
estimate ofthe effective ozone concentration
(17). The parameters were based on linear
regression analysis using the log-transformed
Hom model, and were applied to data mea-
sured at approximately 10C (17), again
taking the SD of the residuals to quantify
uncertainty. Ozonation reduced the median
concentration of viable oocysts in the
Table 1. Model equations for assessment ofthe incidence of infection by C. parvum and renal cell cancer
by bromate.
Equation
Description (unit) Equation no.
Conc of C. parvumoocysts in drinking water(per L) CCIDC CPRAWX 101DRCPCSF+DRCPo 1
Ozone Conc afterfirst contact chamber(mg/L) CO3(0) = O + 1 xD03 2
Ozone residual (mg/L) CO3IT) = CO3(0) x e-dx T 3
Effective ozone Conc (mg/L) C03(efi =e{in[C03(O)ll+In[C03(UI}/2 4
Disinfection of C. parvumoocysts
Withoutozonation DRCP 0 5A
With ozonation DRCP03 k x [CO3(eft]tm x [l1 5B
Daily risk of infection with C. parvum Pinf,cp 1 - e-rxCCPDWX VU 6
Number of persons with one or more infections peryear Nnfcp= Nx[1 - (1 - Pnf,Cp)3651 7
Conc of bromate in drinking water(pg/L) CBr3-DW= 1.46x 10-6x DOC1 18X 8
DO342 XpH5.11 X T0.27 x CB88
Incidence of renal cell cancer peryear NRCC(Nx BrO~,DW 0 9
Conc, concentration.
Table 2. Point estimates and probability distributions of model parameters for assessment of the inci-
dence of infection by C. parvum and renal cell cancer by bromate.
Description (unit)
Conc of C. parvum in raw water(per L)
Decimal reduction of C. parvumby
coagulation-sedimentation-rapid
sand filtration
Ozone dose (mg/L)
Ozone demand parameter(intercept)(mg/L)
Ozone demand parameter(slope)
Contacttime(min)
Ozone decay parameter(per min)
Hom intercept parameterl(L/mg)m/min f]
Hom parameter for concentration
Hom parameter for contact time
Daily consumption of uncooked
drinking water(L/person/day)
Dose-response parameter for C. parvum
Population served
Dissolved organic carbon (mg/L)
pH value
Conc of bromide in rawwater(pg/L)
Daily consumption oftotal drinking water(L/person/day)
Renal cell cancer risk parameter(kg2/3/pg)
Bodyweight(kg)
Symbol
CC RAW
DRCP,CSF
D03
T
d
k
m
n
Vu
N
DOC
pH
C8r-
Vt
q
BW
Median
value
0.044
1.6
3.1
-0.194
0.443
5
0.257
0.2191
0.899
1.059
0.16
Probability distributiona
Lognormal (-3.12, 0.97)
Normal (1.6, 0.4)
Fixed
Normal (pred, 0.091)
Normal (pred, 0.091)
Inverse Gaussian (5, 75)
Normal (pred, 0.239)
log (DR) = normal
(pred, 0.134)
Lognormal (-1.80, 0.99)
0.0037 Lognormal (-5.61, 0.43)
106 Fixed
3.5 Lognormal (1.25, 0.03)
7.5 Fixed
86 Lognormal (4.46, 0.20)
0.81 Lognormal (-0.21, 0.82)
3.0 x 10-6 Custom (bootstrap)
74.5 Men: lognormal (4.39, 0.15)
Women: lognormal (4.21, 0.16)
Abbreviations: Conc, concentration; Pred, predicted value.
&Normal (mean, SD); lognormal (mean, SD on loge scale); inverse Gaussian (mean, shape).
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baseline approximately 7-fold to a median
concentration of 1.6 x 10-4/L.
Bromate. Bromate is only occasionally
present in raw water in The Netherlands
(18); therefore, all bromate in drinking water
is presumably formed during the ozonation
process. Dissolved organic carbon and bro-
mide concentrations in raw water are based
on measurements at an actual plant in The
Netherlands, taking annual variation into
account as an uncertainty factor. We used
the Song et al. (19) model to estimate the
formation of bromate as a function of the
ozone dose and several water quality parame-
ters. We calculated the median bromate
concentration in our scenario as 3.8 pg/L
(Equation 8 in Table 1).
Finally, we calculated the daily ingested
dose of C. parvum oocysts and bromate ions
by multiplication of their concentration in
drinking water with the daily consumption
Vu ofuncooked drinking water (12) or Vtof
total drinking water (20), respectively. The
Vtcommonly used default value of 2 L/per-
son/day is close to the 95th percentile ofthe
distribution in Table 2.
Hazard Characterization
C. parvum. We used the exponential
dose-response model (21) to estimate the
risk ofinfection related to the daily ingested
dose of C. parvum and to estimate the
dose-response parameter, r, (22) from vol-
unteer challenge data (23). A sample of
1,000 simulations of r, obtained by boot-
strapping, is described by a lognormal
distribution. We assumed a population of 1
million inhabitants in the distribution area
who randomly consume drinking water. The
daily risk associated with exposure to C.
parvum is accumulated to estimate the
annual risk ofinfection (Equation 7).
To assess the uncertainty in the annual
risk of infection, we assumed that all model
parameters were independent. Five thousand
replicates ofthe concentration of C. parvum
oocysts in drinking water without ozonation
(CcpDW) were drawn from the distributions in
Equations 1 and 5A. Then we calculated
corresponding estimates ofthe concentration
of C. parvum in drinking water with
ozonation (CCPDW+) by multiplying each
value ofCCP,DW-with a random value for the
reduction factor by ozonation (Equation 5B).
Samples from the distributions of CcpLDW
and CCp,DW+ were then combined with ran-
domly drawn samples of r and Vu, using
identical indices for both series (with and
without ozone). Equation 6 allows us to
compare their values and assess the influence
of ozonation on the risk of infection of any
one individual on any 1 day. We estimated
the annual individual risk of infection by
taking a sample of 365 values of the daily
risk using Equation 7. We repeated this
5,000 times to simulate the distribution of
the annual risk of infection. We then com-
puted the annual incidence of infection as
the annual risk multiplied by the size of the
population at risk.
The annual incidence of infection
without ozonation appears to be approxi-
mately lognormally distributed with a medi-
an of 1,000 cases/million person-years (mpy)
and spans a relatively small range. The 95%
confidence interval (CI) for annual incidence
of infection is 760-1,500 cases/mpy (Figure
IA). The introduction ofozonation leads to
a reduced incidence (median 180 cases/mpy;
CI, 120-260 cases/mpy).
The median values of the incidence of
infection cannot be exactly reproduced by the
simple substitution of median parameter val-
ues in the equations in Table 1. The additive
nature ofEquation 7 implies that the annual
risk is mainly determined by the few occa-
sions on which a high dose is encountered.
Bromate. Exposure to bromate in drink-
ing water is mainly by ingestion; other
routes (inhalation and dermal exposure) are
not described in the literature. To estimate
the excess lifetime risk of renal cell cancer
from exposure to bromate, the WHO (1)
used data by Kurokawa et al. (24) and fitted
the linearized multistage model (LMS) to
extrapolate from high to low doses (25).
Applying this procedure while dividing the
lifetime risk by an average life expectancy of
= 0.75
a'0.75
*1
3 0.25
0.01
2.2 2.4 2.6 2.8 3.0 3.2 -3. Ju -. -i.u -1.5
Log,(no. ofinfections/year) Log9(no. ofcases/year)
Figure 1. Cumulative frequency distributions of the incidence of (A) infection with C. parvum and (B) renal
cell cancer/i mpy.
80 years results in an incidence of0.16 cases
of renal cell cancer/mpy at the calculated
exposure level. For our comparison of
infection and cancer risks associated with the
ozonation of drinking water, the estimated
uncertainty in that risk is needed. Therefore,
we reanalyzed the original data to obtain the
maximum likelihood estimate of excess risk
(26). We added other data by Kurokawa et
al. (217) and recently published data (9)
(Figure 2). The three data sets were fitted by
the LMS model, in which one of the para-
meters, b, which denoted a dose factor, was
allowed to vary between the three studies.
We found that the LMS model did not give
a significantly better fit than the two-stage
model:
F. = a + (1 - a) x [1 - ebix dose-c(b, xdose)2]
where Fi = probability ofrenal cell cancer in
study i, dose = dose [mg KBrO3/(kg body
weight)2/3], a (background response) and c
(shape) = common parameters for all
datasets (for this data set a = 0.019 and c=
0.13), and b -= dose-response parameter fit-
ted to dataset i (b1 = 0.0013, b2 = 0.0028,
and b3 = 0.0091 kg213/mg). For each study
we calculated the corresponding dose associ-
ated with a 10% response (EDIO). The
slopes ofthe three straight lines from the ori-
gin to the ED1O are point estimates for the
three conservative dose-response parameters
of the individual studies (ql = 0.0086, q2 =
0.0026, and q3 = 0.0012 kg213/mg). The
geometric mean of these three values is the
point estimate for the pooled dose-response
parameter (q3 = 0.0030 kg213/mg). We
estimated the uncertainty in q by bootstrap-
ping (28), which resulted in a trimodal
uncertaintydistribution.
We obtained a Monte Carlo sample for
the distribution ofrenal cell cancer incidence
0.1
U
* 0.4
U .
o.;
EDI1
o.I
v wu -v -.w &W
DOe(mg/kg93)
Figure 2. Dose-response data for induction of
renal cell cancer (RCC) in rats by bromate [as mg
KBrO3/(kg bodyweight)2/31 and fitted by two-stage
models. Data symbolized by triangles from
Kurokawa et al. (27); data symbolized by dia-
monds from Kurokawa et al. (24); and data sym-
bolized by circles from DeAngelo et al. (9). The
dose associated with a 10% response (ED10 val-
ues) for each study are based on a simultaneous
fit of all three data sets.
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by substituting 3,000 replicates from all of
the underlying distributions in Equation 9.
Using this model, we estimated that the
median incidence of renal cell cancer was
0.009 cases/mpy, 18 times lower than the
WHO estimate, as based on the LMS
model. This difference is largely (a factor of
10) because we used the maximum likeli-
hood estimate instead of the 95th percentile
of the dose-response parameter and also
because we used a probability distribution for
the consumption ofdrinking water instead of
a conservative point estimate (accounting for
a factor of 1.8). Using three datasets instead
of one has little effect on the median risk.
The renal cell cancer incidence Cl is relatively
wide (0.001-0.075) (Figure 1B), mainly
because the three experimental dose-response
data sets showlarge differences.
Risk Characterization
General. Disease may result in the reduction
ofsurvival time (quantity oflife), the reduc-
tion ofthe quality oflife, or both. We com-
bined these outcomes in a single measure,
the DALY, as originally proposed by Murray
in the global burden ofdisease (GBD) study
(29). The DALY concept is designed as a
generic instrument that produces results on
an interval scale so that meaningful compar-
isons between widely different disease end
points can be made. The loss ofhealthy life-
years in a population, measured in DALYs,
is calculated as:
DALY= LYL + YLD,
where LYL is the number oflife-years lost
due to mortality and YLD is the number of
years lived with a disability, weighed with a
factor between 0 and 1 for the severity ofthe
disability. LYL is calculated by accumulation
over all relevant diseases (z) ofthe product of
d (the number ofdeaths due to a particular
disease) and e (the standard life expectancy
at the age ofdeath due to that disease). YLD
is calculated as the accumulated product of
N(the number ofpersons affected by a non-
lethal disease), L (the duration of this dis-
ease), and W(a measure for its severity). If
necessary, disease processes are subdivided
into several stages with different duration
and severity. Murray (29) and Van der Maas
and Kramers (30) provide further details.
Thus, for a particular agent, the population
health burden is calculated as:
DALY = Xd,e* + XNiLW, -
ii
C. parvum. Table 3 presents the distrib-
utions used for estimation ofthe health bur-
den of infection with C. parvum. Infection
with C. parvum leads to gastroenteritis in
71% of immunocompetent persons (31).
The duration of cryptosporidiosis is usually
reported as 1-2 weeks, but these estimates
are based on cases detected in laboratory
surveillance and may be biased toward
longer duration. In population-based
outbreak studies (6,32) and in volunteer
experiments (23,31), the mean duration of
gastroenteritis is reported to be only 3-6
days. Both types of study (31,33) report
relapses of diarrhea in 40-70% of patients.
To quantify the duration ofcryptosporidio-
sis we used a lognormal distribution with a
median duration of 6 days and a range
between 2 and 30 days.
The disability weight for cryptosporidio-
sis is taken from the GBD study (29). In this
study, a severityweight forwatery diarrhea is
derived using the person trade-off protocol.
Panel members trade offlife-years ofhealthy
persons for healthy years gained by people in
a certain state ofreduced health until a point
ofindifference is reached. The person trade-
off protocol estimates social values of
different health states, and thus is considered
appropriate for the evaluation of health
intervention programs (34).
The mean mortality risk for cryp-
tosporidiosis in the immunocompetent pop-
ulation is estimated as 1/100,000, based on
0.20=........~~~~~~~~~~~~~~~~..................:-c.X~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~....:.......
X. 0.10 .. ...
U.
0.05
0.00
0 5 15 25
Age (years)
experience from the 1993 outbreak in
Milwaukee, Wisconsin (35). Four deaths in
the nonimmunocompromised population
were attributed to the outbreak, which
involved approximately 400,000 persons
(35). The large uncertainty in this estimate is
accounted for by choosing a lognormal dis-
tribution with a high but arbitrary dispersion
factor (log-SD = 1). This distribution has a
median of0.6, a mean of 1, and 95% ofthe
distribution ranges between 0.1 and 4 per
100,000. To estimate the number of life-
years lost by a fatal case ofgastroenteritis, we
used the age distribution for all gastroenteri-
tis deaths in The Netherlands in 1993-1995
and computed the standard life expectancy
in 5-year intervals (29). Figure 3Ashows that
most deaths associated with gastroenteritis
occur in people older than 75 years ofage.
In immunocompromised persons, partic-
ularly in AIDS patients, infection with C.
parvum leads to gastroenteritis in virtually all
cases (38). McGowan et al. (39) reported
that only 30% of AIDS patients have a
remission; the others suffer from cryp-
tosporidiosis until death. We fit a lognormal
model to the reported duration ofdisease in
all patients. There is no formally derived
0.20
>. 0.l5r010~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~..--.,....................'?-0.05~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~..........-...;_.:
0.010
0.00
0 5 15 25 35 45 55 65 75 85 95+
Age(years)
Figure 3. Age distribution of (A) fatal cases of gastroenteritis (36) and (B) patients with renal cell cancer
(37) in The Netherlands.
Table 3. Point estimates and probability distributions of model parameters for assessment of the health
burden of gastroenteritis by infection with C. parvum.
Immunocompetent population Population ofAIDS patientsa
Median Probability Median Probability
Parameter valueb distributionc valueb distributionc
PIinfection 0.71 Normal (0.71, 0.08) 1.00 Fixed
Severity(M 0.054 Lognormal (-2.92, 0.63) 0.16 Lognormal (-1.81, 0.63)
Duration (L) 0.016 Lognormal (-4.14, 0.67) 0.13 Lognormal (-2.03, 0.92)
Case fatality ratio 0.06 per 10,000 Lognormal (-2.80, 1.00) 0.70 Normal (0.70, 0.08)
Life expectancy (e*) 8.2 Customd(13.2, 15.0) 1.0 Lognormal (0.00, 0.83)
TPrevalence 4:10,000. bDuration and life expectancy have unit year; all other parameters are dimensionless. cNormal
(mean, SD); lognormal (mean, SD onlog. scale). dSee Figure 3A.
0.20
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Figure 4. Health burden of (A) infection with C. parvum (per 1,000 cases of infection) and (B) renal cell
cancer (per case).
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severityweight for cryptosporidiosis in AIDS
patients. Because enteritis is more severe in
AIDS patients than in immunocompetent
persons, leading to significant weight loss
and abdominal pain, a larger weight is justi-
fied. The median survival times for patients
with and without cryptosporidiosis are 11.5
and 66 weeks, respectively. Hence, active
cryptosporidiosis reduces the life expectancy
of 70% ofAIDS patients by approximately
1 year (median value). The uncertainty in
this value depends mainly on the survival of
the remission group, which is poorly known
because most patients were still alive when
the studyended. With this restriction, we fit
a lognormal distribution to the reported
survival times. The average prevalence of
AIDS is 0.4/1,000 as for the city of
Amsterdam (40).
Drawing 3,000 replications using the
probability density functions in Table 3 sim-
ulates the probability distribution of the
health burden of gastroenteritis resulting
from infection by C. parvum in drinking
water (Figure 4A). The distribution is highly
skewed to the right, with a median value of
approximately 1.1 healthy life-years/1,000
cases ofinfection and a small but important
probability ofaloss ofup to five healthy life-
years/1,000 cases ofinfection.
Table 4. Point estimates and probability distribu-
tions of model parameters for assessment of the
health burden of renal cell cancer.
Age class
Parameter < 70 years 270years
Percent in class 62(50-65)a 38(35-50)a
No resection 18(10-20) 37 (25-40)
Postoperative death 4(3-5) 4(3-5)
Metastases 19(15-30) 14(10-20)
Death within 5 years 25 (20-30) 48 (40-60)
(no metastases)
Life expectancy 24.7(7.4)b 10.5(2.9)b
Values in percent exceptwhere noted.
&A1l triangular distributions: most likely value (minimum,
maximum). bDiscrete distribution; mean (SD), in years.
derived from Figure 3B.
Bromate. The survival of patients with
renal cell cancer depends primarily on age,
fitness for resection, postoperative survival,
and the presence of metastases (Table 4)
(41,42). Patients with one or more unfavor-
able prognostic factors have a short survival.
Those patients who survive for 5 years after
diagnosis have a normal life expectancy. To
estimate the number oflife-years lost from a
case ofrenal cell cancer, we combined these
prognostic factors with the age distribution
at diagnosis (Figure 3B) and calculated stan-
dardlife expectancies. The morbidityburden
due to renal cell cancer is small as compared
to the mortality burden because death usual-
lyoccurs within a few months after diagnosis
ofa fatal case, and because the quality oflife
after a successful operation is not negatively
influenced. Disability weights for the clinical
phase of unrelated cancers in the Dutch
Public Health Status and Forecast Report
(32) are used to approximate the severity of
renal cell cancer during the first year after
diagnosis to account for the effects of
surgery, therapy, and emotional stress on the
quality of life of survivors. The health bur-
den/case ofrenal cell cancer is simulated by
3,000 samples from the probability
distributions in Table 4. The median health
burden/case ofrenal cell cancer is 10 DALYs,
with a relatively symmetrical distribution
(Figure 4B).
Integration. Table 5 presents point esti-
mates of the health impacts of supplying
drinking water with or without ozonation.
The median incidence of infection with C
parvum of 1,000 cases/mpy leads to 710
cases of gastroenteritis in the immunocom-
petent population and an additional 0.40
cases of cryptosporidiosis in AIDS patients.
The mortality in the immunocompetent
population is low; the AIDS population had
0.29 premature deaths/mpy. Multiplication
of these incidence estimates with disability
weights and the duration ofthe health states
results in an estimate ofthe health loss in the
Table 5. Balancing the risks of drinking water disinfection (point estimates based on median values).
Morbidity Mortality
Hazards N L W YLD d e* LYL DALY
No ozone
Immunocompetent persons 710 0.016 0.054 0.61 0.004 8.2 0.03 0.64
AIDS patients 0.40 0.16 0.16 0.01 0.28 1.0 0.28 0.29
With ozone
Immunocompetent persons 130 0.016 0.054 0.11 0.001 8.2 0.01 0.12
AIDS patients 0.07 0.13 0.16 0.00 0.05 1.0 0.05 0.05
Bromate, renal cell cancer 0.01 See text See text 0.00 0.006 10 0.06 0.06
Health benefita
Immunocompetent persons - - - 0.50 - - 0.02 0.52
AIDS patients - - - 0.01 - - 0.23 0.24
Bromate, renal cell cancer - - - 0.00 - - -0.06 -0.06
Total - - - 0.51 - - 0.19 0.70
Abbreviations: d, number of deaths (per mpy); e*, standard life expectancy at the age of death; L, duration (years); LYL,
lifeyears lost; N, number affected (per 1 mpy); W, severityweight; YLD,years lived with disability.
1No ozone minus with ozone.
scenario without ozonation. Disability by
acute gastroenteritis is the most important
source ofhealth loss for this pathogen (0.61
DALYs), whereas AIDS patients add 0.29
DALYs, mostly due to premature death. By
summation of all effects, we estimated a
health loss by infection of0.93 DALYs/mpy
in the scenario without ozonation. The
introduction of an ozonation step in the
treatment chain does not completely elimi-
nate health risks, although it reduces the
median health loss by gastroenteritis to 0.17
DALYs/mpy. Hence, the median health
benefit of ozonation is 0.76 DALYs/mpy.
The production of bromate leads to 0.01
additional cases ofrenal cell cancer/year. The
health loss ofmorbidity from renal cell can-
cer is negligible; premature death adds 10
life-years lost/fatal case or 0.06 DALYs/mpy,
which is > 10-fold lower than the health
benefits by reducing the risk of infection.
The median net health benefit in this sce-
nario is estimated as 0.70 DALYs/mpy.
Uncertainty and sensitivity analysis.
Figure 5 shows the uncertainty in the esti-
mated health effects. The population health
loss by exposure to C parvum is simulated
by multiplying the matched pairs of
incidence of infection (with and without
ozonation) with samples from the health
burden/case. The median without ozonation
is 1.2 DALYs/mpy (CI, 0.36-4.6) and is
reduced a factor ofapproximately 6 (equal to
the reduction of oocyst concentration) to a
median of 0.20 DALYs/mpy (CI, 0.06-1.1)
by ozonation. Thesevalues are again different
from the point estimates by simple substitu-
tion ofmedianvalues as given inTable 5.
Multiplication ofthe incidence distribu-
tion with the health burden distribution of
renal cell cancer results in the estimated
health loss in the population by exposure to
bromate in the case ofozonation. The medi-
an health loss has a value of 0.10
DALYs/mpy (CI, 0.01-1.1).
Parallel to these simulations, we calculat-
ed the net health benefit ofozonation as the
health loss by gastroenteritis (in the case
r0.75
U.0.5 ,U
S6
Figure 5. Health loss in a population of 1 million by
C. parvum and bromate in drinking water, with
and without ozonation in the production process.
RCC, renal cell cancer.
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without ozonation) minus the sum of the
residual health loss by gastroenteritis and the
health loss of renal cell cancer (in the case
with ozonation). We estimated the net
median health benefit by the probabilistic
model as 0.82 DALYs/mpy; the benefit is
mainly determined by a reduction ofthe risk
of infectious disease. Figure 6 shows the
uncertainty distribution of the net health
benefit, which is skewed to the right; the CI
ranges between -0.22 and 3.7. There is a 5%
chance that the net effect is negative and a
50% chance that it is > 0.82 DALYs/mpy.
Univariate sensitivity analysis (data not
shown) demonstrates that the net health
benefit is most sensitive to (in order of
importance) decimal reduction of C. parvum
by coagulation/sedimentation/filtration
(CSF); dose-response parameter of C.
parvum; consumption of unboiled drinking
water; concentration of C. parvum in raw
water (CCpwRA); pH; and probability, dura-
tion, and severity of enteritis in immuno-
competent individuals. We varied these
parameters by wide but plausible ranges to
evaluate the robustness ofthe overall conclu-
sions and the magnitude of the net health
benefit. In comparison to the baseline sce-
nario, only some extreme parameter values
resulted in the conclusion that ozonation
leads to a net health loss in the population:
high efficiency ofCSF (decimal reduction of
C. parvum . 2.4) and low severityweight for
gastroenteritis in immunocompetent indi-
viduals (< 0.005) in combination with a low
prevalence ofAIDS (< 0.5/10,000). Other
variations in parameter values result in
increased estimates ofhealth gain. Increasing
CCp RAWor reducing the efficiency of CSF
result in health benefits up to 8-12
DALYs/mpy (Figure 7 A, B). The dose-
response parameter rfor C parvum is based
on experimental data with healthy adult vol-
unteers. Other subgroups of the population
(infants and the elderly) might be more sus-
ceptible to infection. A 10-fold increase in r
results in an approximately 10-fold increase
in the net health benefit to approximately 8
DALYs/mpy. Similarly, increasing the
0.75
U
L 0.50 U. 2! U.
unboiled water consumption to 1 L/day
increases the net health benefit to 3
DALYs/1 mpy. The results are less sensitive
to the total water consumption; to reduce
the net health gain to 0 would require per
capita consumption of 5 L/day. The preva-
lence of AIDS was also of interest in our
study. In our scenario, the health loss in
AIDS patients was smaller than in the
immunocompetent population. Ifthe AIDS
prevalence is higher, e.g., 4/1,000 [which is
typical of larger U.S. metropolitan areas
(38)], the health loss in AIDS patients is
much larger, and results in a larger net
benefit of3 DALYs/mpy.
Discussion
This study evaluates the feasibility of inte-
grated measures ofpublic health, such as the
DALY, as a means to assist in the complex
decision-making problem of risk balancing
in drinking water disinfection. A major
advantage ofthe proposed method is that it
leads to a logical, transparent, and compre-
hensive evaluation ofhealth gains and losses
in terms of established public health con-
cepts (quality and quantity oflife and social
magnitude) using time as a unit ofmeasure-
ment. The DALY measure is superior to
comparisons based on annual mortality rates
because it also includes nonlethal end points
and explicitly addresses life and health
expectancy. Information from microbiology,
toxicology, epidemiology, environmental,
and the clinical sciences is integrated in one
single estimate that accounts for the proba-
bilities of different end points occurring. A
similar measure (the quality adjusted life-
year) is extensively used in economic assess-
ment ofmedical technologies and in clinical
decision making. The explicit introduction
of values and preferences when attributing
weights to different diseases adds a new and
possibly controversial dimension. Because
highly prevalent health responses of limited
severity were the most important variables
for the final result, this aspect deserves
detailed attention and communication with
both decision makers and the public.
4.0
_ 3.5
C 3.0
CD2.5
S
L
** 1.5
g 1.0
X 0.5
Z 0.0
-0.5
DALY
Figure 6. Net health benefit of ozonation of drink-
ing water.
DR C.parvum byCSF
Sensitivity analysis demonstrates that varia-
tion of the severity weight of gastroenteritis
in the immunocompetent population does
not affect the conclusion that the health
benefits of ozonation outweigh the health
losses, but the magnitude of the net effect
varies considerably.
DALYs specifically address the health
dimension of a risk management problem.
They do not capture social and cultural val-
ues that are important determinants of risk
perception in the public (e.g., equity, volun-
tariness, and dread) or economic and
technical factors (e.g., costs, benefits, and
feasibility). Such factors will also be taken
into accountwhen taking riskdecisions.
Many potential flaws of the DALY
approach are not unique for this method,
but bear upon health impact assessments in
general, given the present lack ofknowledge
and availability of data. Important but
almost inevitable shortcomings are the
imprecision of population exposure assess-
ments, the unknown and possibly unknow-
able shape of the dose-response curves at
low environmental levels of exposure, and
the translation of this information from
rodents to humans as well as within the
human population. Another important issue
is the internal and external validity of
epidemiologic results.
The limited availability of data leads to
extensive use of simple models to arrive at
final estimates. Many assumptions are made
both qualitatively (which models to use) and
quantitatively (the choice ofdistributions and
parameter values). The uncertainty in the
microbiologic health risk assessment relates
predominantly to the precision of model
parameters and to a lesser extent to the mod-
els themselves. Because relevant health risks
occur at concentrations of microorganisms
that are far below the limit of detection of
current analytical methods, validation of
model predictions by comparison with mea-
sured data is not possible. On the other
hand, the uncertainties of the chemical risks
pertain to the level of construct validity. Is
carcinogenesis in laboratory animals exposed
-h
0 W=
.50
m2
0 0.2 0.4 0.6 0.8 1
Concentration ofC.parum in rawwater(oocysts/L)
Figure 7. Sensitivity of net health benefit of ozonation to (A) CSF and (B) the occurrence of C. parvum in
rawwater. DR, decimal reduction.
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to high doses ofbromate really predictive of
effects in humans who are exposed to con-
centrations many orders ofmagnitude lower
and, ifso, what is the actual risk? The differ-
ence in this study between the conventional
conservative approach designed to derive safe
maximum allowable concentrations, and the
probabilistic approach designed to estimate
the probability distribution of the response
parameter for renal cell cancer, illustrates
one ofthe consequences ofthis uncertainty.
Not only does the risk of renal cell cancer
appear to be reduced by a factor of 18, but
the final conclusion is also strongly affected
by the choice of the extrapolation method.
None ofthe models in this study can be rig-
orously validated, but we believe that they
reflect the best available knowledge. The
DALY methodology adds a public health
dimension to the process of risk assessment
that may make the outcomes more useful for
risk managers. Also, our method does not
impose any constraints on allowing the
incorporation offuture information.
In our standard scenario, the estimated
health benefits by pathogen reduction
appear to outweigh the health losses by bro-
mate formation. The absolute level of the
net health benefit is approximately 1
DALY/1 mpy, which is a relatively small
fraction of the total healthy life expectancy.
For comparison, we refer to the commonly
accepted 10-6 lifetime cancer risk by expo-
sure to genotoxic carcinogens. Using renal
cell cancer data as an example, this risk
equals a health loss of 10-6 x 10 DALYs/80
life-years = one-eighth DALY/mpy. The
health benefit in our case study is larger than
this value; therefore, ozonation is indicated.
The cost-effectiveness of achieving this
benefit has notyet been evaluated.
Several factors may influence the size of
the final health benefit. The microbiologic
risks are most sensitive to the concentration
of oocysts of C. parvum in the raw water.
Many drinking water supplies in the world
are challenged with considerably higher
levels than our hypothetical supply, and in
these cases ozonation would yield a consid-
erable public health benefit. However, there
are also many drinking water supplies in
which the concentration of bromate would
be higher than our estimate, leading to
higher health losses in achieving the desired
disinfection goal. Bromate levels can be
partially controlled by the adjustment ofpH
and optimization of the dose/contact time
combination. If a high level of inactivation
of C. parvum oocysts must be achieved, it
will certainly lead to increased toxicologic
risks. Our results highlight the need for raw
water quality protection and a multiple
barrier approach in treatment to reduce the
need for disinfection as much as possible.
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